


Express Mail Label No.: EV781047910US  
Date of Deposit: July 25, 2006

Page 1 of 4



Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB (12-97)  
OMB 0651-0031

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	06/19/03
	First Named Inventor	Miller
	Group Art Unit / Conf. No.:	1621 / 8627
	Examiner Name	Yevgeny Valenrod
	Attorney Docket Number	24852-501 CIP

#### U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
YV	A24*	4,690,918	09/01/87	Beppu, et al.			
YV	A25*	5,654,333	08/05/97	The United States of America as represented by the Department of Health and Human Services <i>SAMEO</i>			
YV	A26*	6,239,176	05/29/01	Beacon Laboratories, Inc. et al. <i>Nudelmann et al.</i>			
YV	A27*	6,262,116	07/17/01	Stoan-Kettering Institute for Cancer Research <i>Pardoll et al.</i>			
YV	A28*	6,451,334	09/17/02	Perrine			
YV	A29*	6,495,719	12/17/02	CircaGen Pharmaceutical <i>LAO-Harjest et al.</i>			
YV	A30*	2003/0114525	06/19/03	Kammer, et al.			
YV	A31*	2004/0132643	07/08/04	Fojo, et al.			
YV	A32*	2004/0167184	08/26/04	Wlech, et al.			

#### FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
YV	B14*	WO 98/39965	Beacon Laboratories, LLC	09/17/98	X
YV	B15*	WO 02/15921	The Government of the United States of America	02/28/02	X
YV	B16*	WO 02/055017	Wake Forest University	07/18/02	X

#### NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
YV	C84*	"Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.
YV	C85*	"Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.
YV	C86*	"Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development", September 20, 2002.